Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.
Jeffrey Lancet, MD
Advertisement
Articles by Jeffrey Lancet, MD
Advertisement
Latest Updated Articles
Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AMLFebruary 24th 2017
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5